Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 7/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | GPR35 | Q9HC97 | 4/20 | 0.38 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.33 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26739353 | 0.80 | DAO (0.37) | DAOALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL2064339 | 0.77 | DAO (0.59) | DAOALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL16755838 | 0.75 | DAO (0.61) | DAOALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL27760644 | 0.75 | DAO (0.45) | DAOALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL4987918 | 0.73 | DAO (0.44) | DAOALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL3887912 | 0.73 | DAO (0.41) | DAOALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL27845494 | 0.72 | CYP2A6 (0.36) | ALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL16755964 | 0.70 | GPR35 (0.43) | DAOALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL26740078 | 0.69 | DAO (0.37) | DAOALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL12271839 | 0.69 | L3MBTL1 (0.42) | DAOALDH1A1MEN1KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220289727-A1 | ENZYME INHIBITORS | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2022-09-15 | — | — | US | disclosed |
| EP-4017850-A1 | ENZYME INHIBITORS | Kalvista Pharmaceuticals Limited (GB) | 2022-06-29 | — | — | EP | disclosed |
| CN-114258392-A | Enzyme inhibitors | 卡尔维斯塔制药有限公司 | 2022-03-29 | — | — | CN | disclosed |
| WO-2021032935-A1 | ENZYME INHIBITORS | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2021-02-25 | — | — | WO | disclosed |
| WO-2021032938-A1 | ENZYME INHIBITORS | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2021-02-25 | — | — | WO | disclosed |
| WO-2021032938-A1 | ENZYME INHIBITORS | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2021-02-25 | — | — | WO | disclosed |
| WO-2021032935-A1 | ENZYME INHIBITORS | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2021-02-25 | — | — | WO | disclosed |
| EP-2222667-B1 | NOVEL THIOPHENE DERIVATIVES AS AGONISTS OF S1P1/EDG1 | ACTELION PHARMACEUTICALS LTD (CH) | 2013-02-20 | — | — | EP | disclosed |
| US-8148410-B2 | Thiophene derivatives as agonists of S1P1/EDG1 | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-04-03 | — | — | US | disclosed |
| US-20100261702-A1 | THIOPHENE DERIVATIVES AS AGONISTS OF S1P1/EDG1 | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-10-14 | — | — | US | disclosed |
| EP-2222667-A2 | NOVEL THIOPHENE DERIVATIVES AS AGONISTS OF S1P1/EDG1 | Actelion Pharmaceuticals Ltd. (CH) | 2010-09-01 | — | — | EP | disclosed |
| WO-2009074950-A2 | THIOPHENE DERIVATIVES AS AGONISTS OF S1P1/EDG1 | ACTELION PHARMACEUTICALS LTD (CH) | 2009-06-18 | — | — | WO | disclosed |
| US-4996227-A | Administering nontoxic antitumor agents | UNIVERSITY OF CINCINNATI (US) | 1991-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261702-A1 | THIOPHENE DERIVATIVES AS AGONISTS OF S1P1/EDG1 | S1PR1, S1PR3, S1PR5 | DAO 4564/4885ALDH1A1 1141/4885MEN1 1461/4885 |
| US-20220289727-A1 | ENZYME INHIBITORS | SERPINB1, ACE, GAA | DAO 245/4885ALDH1A1 237/4885MEN1 1698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.